Pharmacytimes: Condition Center: ADHD http://www.pharmacytimes.com/condition-resources/adhd/condition-rss ADHD en-us Mon, 25 Jun 2018 02:06:50 UTC Mon, 25 Jun 2018 02:06:50 UTC ADHD: Symptoms, Causes, Management, and Medication http://www.pharmacytimes.com/publications/issue/2018/March2018/adhd-symptoms-causes-management-and-medication Attention-deficit/hyperactivity disorder is a neurodevelopmental mental disorder characterized by difficulty paying attention, excessive activity, and/or impulsivity that interferes with development and/or functioning. 1:00 PM, Wed March 28, 2018 ADHD Prescriptions Rise Among Reproductive-Age Women http://www.pharmacytimes.com/resource-centers/womens-health/adhd-prescriptions-rise-among-reproductiveage-women More research needed to determine if ADHD medication is safe to take before and during pregnancy.<br /> &nbsp; 8:49 AM, Tue January 30, 2018 Medication Management in Schools: Pharmacist Involvement Can Improve Outcomes http://www.pharmacytimes.com/resource-centers/asthma/medication-management-in-schools-pharmacist-involvement-can-improve-outcomes Between 10% and 20% of students in kindergarten through high school have chronic illness. 8:00 AM, Tue December 5, 2017 Mydayis http://www.pharmacytimes.com/publications/issue/2017/November2017/mydayis The fda has approved mydayis (mixed salts of a single-entity amphetamine product, by Shire) to treat attention deficit hyperactivity disorder (ADHD) in patients 13 years or older. 8:00 AM, Fri November 24, 2017 FDA OKs ADHD Medication http://www.pharmacytimes.com/product-news/fda-oks-adhd-medication 12:47 PM, Fri September 15, 2017 ADHD Drug Gets FDA Nod http://www.pharmacytimes.com/news/adhd-drug-gets-fda-nod Mydayis is not for use in children 12 years and younger. 3:55 AM, Wed June 21, 2017 FDA Approves First Orally Dissolvable Methylphenidate Tablets for ADHD http://www.pharmacytimes.com/product-news/fda-approves-first-orally-dissolvable-methylphenidate-tablets-for-adhd The FDA has approved Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets from Neos Therapeutics, the company announced in a press release.&nbsp; 4:45 PM, Tue June 20, 2017 FDA Okays Generic Strattera http://www.pharmacytimes.com/resource-centers/adhd/fda-oks-generic-strattera The FDA today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder.&nbsp; 4:53 PM, Tue May 30, 2017 5 Interesting Medication Case Reports - Part 3 http://www.pharmacytimes.com/contributor/timothy-o-shea/2017/04/5-interesting-medication-case-reports---part-3 This article highlights 5 published case reports that document unusually high doses of medications that are not often seen in clinical practice. 9:54 PM, Wed April 26, 2017 Exercise May Alleviate ADHD Symptoms http://www.pharmacytimes.com/publications/issue/2017/March2017/exercise-may-alleviate-adhd-symptoms A recent study has indicated that even small amounts of exercise can have psychological benefits for adults who experience ADHD symptoms. 3:55 PM, Mon March 20, 2017 Medication Can Reduce Risky Behavior in Kids and Teens with ADHD http://www.pharmacytimes.com/publications/issue/2017/March2017/medication-can-reduce-risky-behavior-in-kids-and-teens-with-adhd Although children and teenagers who are diagnosed with attention-deficit/hyperactivity disorder are more likely to engage in risky behaviors such as dangerous driving and drug use, a recent study has suggested that the use of ADHD medications could help prevent these behaviors. 3:55 PM, Mon March 20, 2017 ADHD Candidate Drug Did Not Meet Primary Endpoint http://www.pharmacytimes.com/news/adhd-candidate-drug-did-not-meet-primary-endpoint The drug failed to demonstrate&nbsp;a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners&rsquo; Adult ADHD Rating Scales (CAARS). 2:31 PM, Tue January 17, 2017 Mylan Launches Generic Concerta and Zovia in the US Market http://www.pharmacytimes.com/product-news/mylan-launches-generic-concerta-and-zovia-in-the-us-market Mylan launched 2 generic pharmaceutical products at the end of December for the treatment of attention deficit hyperactivity disorder (ADHD) and the prevention of pregnancy.&nbsp; 1:28 PM, Thu December 29, 2016 Generic Dexedrine from Mylan Now Available http://www.pharmacytimes.com/product-news/generic-dexedrine-from-mylan-now-available Mylan's generic version of Dexedrine is now available at US pharmacies in 3 dosage strengths. 7:00 AM, Mon August 8, 2016 QuilliChew ER http://www.pharmacytimes.com/publications/issue/2016/July2016/QuilliChew-ER The FDA has approved Quillichew ER extended-release chewable tablets for the treatment of ADHD in patients 6 years and older. 5:08 AM, Thu July 14, 2016 Dyanavel XR http://www.pharmacytimes.com/publications/issue/2016/June2016/Dyanavel-XR Dyanavel XR extended-release oral suspension has received FDA approval for the treatment of ADHD in patients 6 years and older. 3:12 AM, Fri June 10, 2016 2 Chronic Health Conditions on the Rise Among Children http://www.pharmacytimes.com/news/2-chronic-health-conditions-on-the-rise-among-children Chronic health conditions are on the rise among children, especially those living in poverty. 11:00 PM, Mon May 30, 2016 ADHD Is It the Brain or Something Else? http://www.pharmacytimes.com/publications/issue/2016/March2016/ADHD-Is-It-the-Brain-or-Something-Else Because of the multifactorial nature and strong genetic component of ADHD, practitioners continue to speculate whether ADHD is due solely to improper brain functioning. 10:30 PM, Wed March 16, 2016 5 Things to Know About Adult ADHD http://www.pharmacytimes.com/news/5-things-to-know-about-adult-adhd Attention-deficit/hyperactivity disorder has long been viewed as a pediatric condition, but it often lasts into adulthood. 9:52 PM, Tue February 2, 2016 Pregnant Women on Antidepressants Need Not Fear ADHD, Autism Risk http://www.pharmacytimes.com/resource-centers/womens-health/pregnant-women-on-antidepressants-need-not-fear-adhd-autism-risk Exposure to antidepressants during pregnancy does not impact a baby's risk for autism or attention-deficit/hyperactivity disorder after birth. 10:00 PM, Mon January 18, 2016